AIFM2 and prostate cancer: Moreover, preclinical studies in prostate cancer models have demonstrated that pharmacologic or genetic inhibition of FSP1 markedly restores tumor sensitivity to abiraterone, accompanied by activation of ferroptosis and accumulation of lipid-reactive oxygen species (ROS) [87,88].